Development of Anti-DUSP13 Antibody for Acquired Gefitinib Resistance in Lung Adenocarcinoma
碩士 === 國立臺灣大學 === 醫學檢驗暨生物技術學研究所 === 102 === Gefitinib is an EGFR-tyrosine kinase inhibitor that has excellent antitumor activity in the advanced non-small-cell lung cancer (NSCLC) with EGFR-activating mutations. Despite the dramatic response to such inhibitors, 30-40% of patients seem to have intrin...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | en_US |
| Published: |
2014
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/42891389523009595536 |